Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

CRC × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 459 Melanoma 298 Squamous Cell Carcinoma of Head and Neck 232 Parkinson Disease 4, Autosomal Dominant Lewy Body 188 Neoplasms 181 Breast Neoplasms 162 Triple Negative Breast Neoplasms 161 Neoplasm Metastasis 155 Lung Neoplasms 146 Colorectal Neoplasms 141 Carcinoma, Renal Cell 132 Head and Neck Neoplasms 121 Stomach Neoplasms 102 Ovarian Neoplasms 97 Carcinoma, Transitional Cell 90 Pancreatic Neoplasms 81 Urinary Bladder Neoplasms 80 Carcinoma, Hepatocellular 75 Endometrial Neoplasms 70 Uterine Cervical Neoplasms 64 Esophageal Neoplasms 58 Recurrence 50 Prostatic Neoplasms 49 Sarcoma 43 Carcinoma 41 Small Cell Lung Carcinoma 38 Glioblastoma 38 Carcinoma, Squamous Cell 38 Hodgkin Disease 35 Cholangiocarcinoma 34

Interventions

Leucovorin 2 Irinotecan 2 Fluorouracil 2 Cetuximab 2 spartalizumab 1 pembrolizumab 1 camrelizumab 1 Radiosurgery 1 Oxaliplatin 1 Oncolytic Virotherapy 1 KD025 1 IFL protocol 1 HLX07 1 Folfox protocol 1 Drug Therapy 1 CCT239065 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡